News headlines about AstraZeneca (NYSE:AZN) have been trending somewhat positive recently, according to Accern. Accern scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AstraZeneca earned a news impact score of 0.25 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.8979539026924 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern’s rankings:
- Compugen inks antibody development deal with AstraZeneca; shares ahead 11% premarket (seekingalpha.com)
- Compugen, AstraZeneca unit in cancer drug development deal (finance.yahoo.com)
- AstraZeneca (AZN) Downgraded by Zacks Investment Research to “Sell” (americanbankingnews.com)
- One of America’s most popular drugs — first aimed at schizophrenia — reveals the issues of ‘off-label’ use (washingtonpost.com)
- AstraZeneca’s Symbicort ([budesonide + formoterol]) Drug Analysis Report 2018 – ResearchAndMarkets.com (businesswire.com)
Shares of NYSE AZN traded down $0.28 during midday trading on Monday, reaching $34.69. The stock had a trading volume of 3,709,305 shares, compared to its average volume of 4,086,131. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62. The stock has a market cap of $88,575.38, a PE ratio of 8.11, a price-to-earnings-growth ratio of 1.81 and a beta of 0.62. AstraZeneca has a 12-month low of $28.43 and a 12-month high of $36.70.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Friday, February 2nd. The company reported $1.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.86. The firm had revenue of $5.78 billion during the quarter, compared to analysts’ expectations of $5.49 billion. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.21 earnings per share. research analysts expect that AstraZeneca will post 1.7 EPS for the current year.
The company also recently disclosed a semiannual dividend, which was paid on Monday, March 19th. Stockholders of record on Friday, February 16th were paid a $0.95 dividend. The ex-dividend date of this dividend was Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s dividend payout ratio (DPR) is presently 32.01%.
A number of analysts have commented on the stock. BMO Capital Markets set a $40.00 target price on shares of AstraZeneca and gave the company a “buy” rating in a report on Thursday, March 22nd. Leerink Swann upped their target price on shares of AstraZeneca from $36.00 to $38.00 and gave the company a “market perform” rating in a report on Tuesday, February 6th. Sanford C. Bernstein upped their target price on shares of AstraZeneca from $40.00 to $42.00 and gave the company an “outperform” rating in a report on Monday, February 5th. ValuEngine cut shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 7th. Finally, Zacks Investment Research raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. AstraZeneca has an average rating of “Hold” and a consensus price target of $36.32.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Enterprise Leader and is the property of of Enterprise Leader. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://theenterpriseleader.com/2018/04/02/astrazeneca-azn-earning-somewhat-positive-press-coverage-report-shows.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.